Bristol Myers Squibb (NYSE:BMY) today announced detailed results from True North, a pivotal, placebo-controlled Phase 3 trial evaluating oral Zeposia (ozanimod) as an induction and maintenance therapy in adult patients with moderate to severe ulcerative colitis (UC). True North met both primary endpoints, demonstrating highly statistically significant and clinically meaningful […]
INVESTMENT
Compass Pathways IPO marks the first liquidity event for WPSS. WPSS invested in Compass Pathway’s series B alongside Founders Fund and McQuade/Otsuka. Compass Pathways IPO marks the first liquidity event for WPSS. WPSS invested in Compass Pathway’s series B alongside Founders Fund and McQuade/Otsuka. Compass Pathways IPO marks the first […]